Evotec AG has entered into a collaboration with Probiodrug AG, a biopharmaceutical company focused on drug development for major age-related diseases. Evotec will set up and validate assays to support preclinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease (AD). Glutaminyl cyclase is a novel enzyme target discovered by Probiodrug, and plays a role in the pathogenesis of AD as well as potentially other diseases.   Dr. Mario Polywka, chie...